Eikon Therapeutics
Eikon Therapeutics raises $350.7M Series D at $3B valuation
Quick Facts
Eikon Therapeutics: Series D Funding Round
Eikon Therapeutics has successfully raised $350.7M in Series D funding, reaching a valuation of $3B.
Company Overview
Drug discovery using advanced microscopy
Funding Details
The Series D round was led by Andreessen Horowitz Bio, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Hayward, CA
- Founded: 2019
- Employees: 200+
- Category: HealthTech
Investment
Eikon Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Andreessen Horowitz Bio: Verified investor in Series D
- ARCH Venture Partners: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
